Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Operating Costs and Expenses:
General and administrative	$ 2,147	$ 2,222	$ 4,573	$ 3,935
Research and development	7,164	7,508	15,319	14,002
Total Operating Costs and Expenses	9,311	9,730	19,892	17,937
Loss from Operations	(9,311)	(9,730)	(19,892)	(17,937)
Other Income (Expense):
Change in fair value of warrant liability	3,513	(3,895)	3,015	(8,047)
Interest income	34	2	35	3
Total Other Income (Expense)	3,547	(3,893)	3,050	(8,044)
Net Loss	(5,764)	(13,623)	(16,842)	(25,981)
Net Loss Attributable to Non-controlling Interest	(82)	0	(315)	0
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries	$ (5,682)	$ (13,623)	$ (16,527)	$ (25,981)
Net Loss Per Share - Basic (in dollars per share)	$ (0.06)	$ (0.19)	$ (0.18)	$ (0.36)
Net Loss Per Share - Dilutive (in dollars per share)	$ (0.10)	$ (0.19)	$ (0.21)	$ (0.36)
Weighted average number of shares outstanding during the period - Basic (in shares)	91,015,733	72,736,829	90,921,243	72,674,650
Weighted average number of shares outstanding during the period - Dilutive (in shares)	93,930,540	72,736,829	92,651,215	72,674,650